GlassScriptPhysician profile
Corine S Cicchetti
NPI 1639339716
$15,619.84
in general payments reported to CMS, 2019-2025
35 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what 94% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $893 · 2021: $3,742 · 2022: $4,121 · 2023: $1,480 · 2024: $2,611 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,405.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,354.44 | 2021-2025 | Octrode, Proclaim, Axium |
| Abbvie INC. | $1,155.19 | 2021-2025 | Botox, Ubrelvy |
| Nevro Corp. | $1,146.54 | 2020-2023 | Senza |
| Saluda Medical Americas, INC. | $1,097.94 | 2023-2025 | Evoke, Evoke Scs |
| Spr Therapeutics, INC | $939.63 | 2023-2025 | Sprint Pns System |
| Allergan, INC. | $714.17 | 2019-2022 | |
| Si-Bone, INC. | $688.44 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $574.05 | 2021-2025 | Xeomin |
| Galderma Laboratories, L.P. | $525.49 | 2023-2025 | |
| Boston Scientific Corporation | $481.46 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Revance Therapeutics, INC. | $382.93 | 2024-2025 | Daxxify |
| Merz North America, INC. | $244.96 | 2019-2025 | |
| Relievant Medsystems, INC. | $174.36 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $163.64 | 2020-2025 | Dysport |
| Spinal Simplicity, LLC | $149.50 | 2024 | Ha Minuteman G3-R |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $146.37 | 2024 | Mild Device Kit |
| Vertos Medical, INC. | $83.33 | 2024 | Mild Device Kit |
| Bioventus LLC | $67.28 | 2022-2024 | Durolane |
| Axsome Therapeutics, INC. | $57.13 | 2025 | Symbravo |
| Foundation Fusion Solutions, LLC | $55.89 | 2024 | |
| Zyla Life Sciences, INC. | $52.05 | 2019-2020 | |
| Depuy Synthes Sales INC. | $46.52 | 2020 | |
| Ferring Pharmaceuticals INC. | $44.72 | 2019-2022 | |
| Pacira Therapeutics, INC. | $43.78 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $33.69 | 2025 | |
| Fidia Pharma USA INC. | $23.32 | 2023 | Hymovis, Triluron |
| Xeris Pharmaceuticals, INC. | $22.08 | 2024 | Keveyis |
| Medtronic, INC. | $21.96 | 2024 | Intellis Adaptivestim |
| Pacira Pharmaceuticals Incorporated | $21.73 | 2023 | Iovera, Zilretta |
| Assertio Therapeutics, INC. | $19.70 | 2020 | |
| Botanix Sb INC | $19.27 | 2025 | Sofdra |
| Mdd US Operations, LLC | $17.96 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.35 | 2019 | |
| Pfizer INC. | $16.81 | 2019 | |
| Avanos Medical | $16.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corine Cicchetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.